Hutchmed China Ltd ADR down 5.05% to $12.41 after earnings

Hutchmed China Ltd ADR (HCM) said ahead of Monday’s opening that it lost $0.96 per share in FALSE 2022. The company reported revenue of $202 million.

In the same quarter a year ago, the company lost $0.7 per share on revenue of $157.4 million.

The stock is down 5.05% at $12.41 after the report.

Profits at Hutchmed China Ltd ADR grew faster than revenues, signaling widening profit margins.

Wall Street analysts had a strong average buy rating on the stock ahead of the report.

InvestorsObserver gives the stock a bullish sentiment score at the moment based on recent trades.

Before the report InvestorsObserver gave the stock an overall rating of 59. Meanwhile, the average Wall Street analyst rated the stock as a strong buy.

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Its reportable segments include Innovation Platform and Business Platform. The company has a portfolio of several cancer drug candidates currently in clinical trials around the world and an extensive commercial infrastructure in its home market, China. The business platform includes a prescription drug business and a consumer healthcare business for over-the-counter drugs.